Lymphoma, Extranodal NK-T-Cell Clinical Trial
Official title:
Pembrolizumab and Radiotherapy for Previously Untreated Patients With Limited Stage NK/T Cell Lymphoma Who Are Not Eligible to Chemotherapy
Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with complete remission, partial response and stable disease will continue with pembrolizumab maintenance up to 2 years. Patients will be followed up to 4 years from treatment start.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2026 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Confirmed histological diagnosis of NK/T Cell Lymphoma - No previous anti-lymphoma treatment - Age = 18 years - Ann Arbor stage I-II - At least one measurable/evaluable site after diagnostic biopsy before treatment start - At least one of the following high-risk features: age > 60 years, elevated LDH, stage II, primary tumor invasion - Patient ineligible to receive full dose standard chemotherapy - ECOG performance status of 0-1 - Signed Informed consent - Ability to comply with the protocol - Adequate hematological and organ function; - Tumor tissue (fresh preferred, archival tissue is also acceptable) - For women of childbearing potential a negative pregnancy test on day 1 of cycle 1 and agree to adopt an adequate measure to avoid pregnancy during study treatment and for at least one year from end of treatment - For men agreement to remain abstinent or to use barrier contraception Exclusion Criteria: - Advanced stage disease (AA stage III-IV) - Extranasal type NKTCL - History of autoimmune disease - History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer). - History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis - Active infection requiring systemic therapy - Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina. - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent - HBsAg, HCV or HIV positivity. Positive serology is admitted for HBV and HCV but DNA/RNA test must be negative - Administration of a live attenuated vaccine within 4 weeks before cyle 1 day 1. Patients must not receive live, attenuate vaccines, including influenza vaccines at any time during study. - Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed. - Evidence of suspect of CNS disease - Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound Pembrolizumab itself or to the excipients in its formulation). - Has had an allogenic tissue/solid organ transplant - Known history of active TB (Bacillus Tuberculosis) |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Rui-Jin Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
International Extranodal Lymphoma Study Group (IELSG) |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) rate at 2 years - The proportion of patients without disease progression after 2 years from treatment start | Response will be assessed using international criteria for response assessment in lymphomas (Cheson 2014) and their update for patients receiving checkpoint inhibitors (Cheson 2016 Lyric) | 2 years from treatment start | |
Secondary | Complete remission rate (CRR) - Proportion of patients with complete responses | CRR defined according to Cheson 2014 criteria | After 4 months from treatment start (End of Induction phase), Maintenance Phase:every 4 months during the first year and then every 6 months until end of treatment. Follow up: every 4 months during first year, then every 6 months during second year | |
Secondary | 2-year Event-free survival - Proportion of patient without disease related events after 2 years from treatment start | 2 years from treatment start | ||
Secondary | Treatment related mortality - Number of treatment related deaths | From informed consent signature to 90 days after the last study treatment administration | ||
Secondary | 2-year Overall survival - Proportion of patients alive after 2 years from treatment start | 2 years from treatment start | ||
Secondary | Rate of adverse events - Analysis of incidence, severity and relationship of adverse events | Adverse Events severity will be classified according to the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V. 5.0 | From Informed Consent signature to 30 days for AEs or 90 for SAEs after end of treatment | |
Secondary | Overall Response Rate (ORR) - calculated as the sum of the complete and partial remission rates | ORR defined according to Cheson 2014 criteria | After 4 months from treatment start (End of Induction phase) Maintenance Phase: every 4 months during the first year and then every 6 months until end of treatment. Follow up: every 4 months during first year, then every 6 months during second year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02878278 -
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation
|
Phase 2 | |
Terminated |
NCT01948180 -
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
|
Phase 2 | |
Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
Terminated |
NCT02359162 -
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
|
Phase 3 | |
Recruiting |
NCT02080234 -
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
|
Phase 2 | |
Completed |
NCT03049449 -
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
|
Phase 1 | |
Not yet recruiting |
NCT03051555 -
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
|
N/A | |
Not yet recruiting |
NCT03051542 -
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
|
N/A | |
Recruiting |
NCT03154918 -
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT01933282 -
MESA Treatment for NK/T Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02533323 -
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
|
Phase 2 | |
Active, not recruiting |
NCT03439501 -
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
|
Phase 2 | |
Recruiting |
NCT02859402 -
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
|
Phase 2 |